Urogen Pharma Ltd   (URGN)
Other Ticker:  
Price: $17.7700 $-0.56 -3.055%
Day's High: $18.19 Week Perf: -1.06 %
Day's Low: $ 16.30 30 Day Perf: 13.18 %
Volume (M): 371 52 Wk High: $ 24.13
Volume (M$): $ 6,586 52 Wk Avg: $13.53
Open: $17.32 52 Wk Low: $7.75

 Market Capitalization (Millions $) 574
 Shares Outstanding (Millions) 32
 Employees -
 Revenues (TTM) (Millions $) 76
 Net Income (TTM) (Millions $) -105
 Cash Flow (TTM) (Millions $) 91
 Capital Exp. (TTM) (Millions $) 0

Urogen Pharma Ltd
Urogen Pharma Ltd is a pharmaceutical company that specializes in the development and commercialization of innovative therapies for urological and urogenital diseases. The company focuses on diseases such as bladder cancer, overactive bladder, and prostate cancer. Urogen Pharma aims to improve the quality of life for patients by providing effective and safe treatments. The company utilizes advanced technologies and research to develop novel drug candidates and therapies, with a focus on precision medicine and targeted therapies. Urogen Pharma is dedicated to addressing unmet medical needs in the urology field and improving patient outcomes.

   Company Address: 400 Alexander Park Drive Princeton 8540 NJ
   Company Phone Number: 768-9780   Stock Exchange / Ticker: NASDAQ URGN
   URGN is expected to report next financial results on March 23, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Urogen Pharma Ltd

URGN Plunges into New Financial Realm with Incredible Q3 2023 Figures

Urogen Pharma Ltd, a major player in the pharmaceutical preparations industry, has announced its financial results for the third quarter of 2023. Despite a decline in the industry's overall revenue, Urogen Pharma saw an impressive increase in its revenue, a significant reduction in its loss per share, and improved earnings per share (EPS). This article will delve into the financial figures and evaluate the current state of Urogen Pharma in context.
Financial Results:
During the third quarter of 2023, Urogen Pharma reported a loss per share of $-0.68, a significant improvement compared to the $-1.13 loss per share recorded during the same quarter a year ago. Additionally, EPS improved from $-1.03 per share in the previous quarter. These positive figures indicate that Urogen Pharma's cost management and operational efficiency have improved over time.

Urogen Pharma Ltd

Fiscal Span Ending June 30, 2023 Marks Evanescence of Deficit for Urogen Pharma Ltd

The stock market has always been a rollercoaster ride, with its ups and downs causing investors to experience a mix of emotions. However, amidst all the uncertainties, there are always shining stars that emerge, and Urogen Pharma Ltd is one such company that stands out in the second quarter of 2023.
For the fiscal span closing June 30, 2023, Urogen Pharma Ltd saw a decrease in loss per share, demonstrating a positive trend. With a decrease from $-1.18 to $-1.03 per share compared to a year ago, it is evident that the company is moving towards better financial stability. Moreover, the improvement in EPS from $-1.30 in the prior reporting season further illustrates the company's ability to navigate the market successfully.

Urogen Pharma Ltd

Urogen Pharma Ltd Sees Surge in Revenue, but Profitability Remains Elusive

The pharmaceutical industry is one that is closely monitored because it has a direct impact on the health of people. In the latest financial period, one of the major pharmaceutical preparations companies announced that it had experienced a surge in revenue by 26.747%. This brought their revenue to $17.19 million, which shows a positive trend for the company. However, while the company experienced growth in revenue, it also saw a loss per share at $-1.30 per share. This was a significant increase compared to the prior period when the loss was at $-1.23 per share. In addition, their revenue decreased by -4.975% from $18.09 million in the prior fiscal period.
The Urogen Pharma Ltd experienced a net loss of $-30.213 million in the most recent fiscal period. This was a larger loss compared to the previous year when it was $-28.392 million. It is important to note that Urogen Pharma Ltd is expected to report its next financial update on August 10, 2023. The cumulative net loss for Urogen Pharma Ltd during the 12 months ending in the first quarter of 2023 was $-112 million. This resulted in a negative return on investment (ROI) of -102.16%. Within the healthcare sector, there were 559 other companies that had a higher return on investment.


Urogen Pharma Ltd's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com